B C P – Statement
(Business Continuity Planning)

Product group: MCC, Starch, Lactose, Inhalation, Biopharma and Superdisintegrants

All products manufactured by:

DFE Pharma GmbH & Co. KG

Dear Customer,

Herewith we confirm that Business Continuity Planning is a vital activity for DFE Pharma GmbH & Co. KG. Our activities in this field of responsibility start with considering the impact of a potential disaster (e.g. force majeure risk, pandemic outbreak) as well as understanding the underlying risks.
Based on this DFE Pharma is actively identifying the essential business functions and assessing the disaster risks that could adversely affect our business continuity.

DFE Pharma has systems in place to guarantee good communication with our customers should such a disaster cause a change to DFE Pharma normal business practice. It is our base principle to endeavor to maintain supply to our customers by rapid implementation of the necessary actions plans for incident management and disaster recovery.

This statement substitutes all previous versions issued for the brand names mentioned above.
We trust this information, which is made up to the best of our knowledge, will be helpful to you.

Name : Wilbert van de Rakt
Job title : Quality Director
Signature :

This document is controlled by a validated, electronic system and is valid without signature.
The above facsimile signature is only for display.

DFE Pharma GmbH & Co. KG
Klever Strasse 187, 47574 Goch, Germany, P.O. Box 20 21 20, 47568 Goch, Germany, T. +49 2823 9288 770, F. +49 2823 9288 7799

The document is an uncontrolled copy and is valid only at the time of distribution. Timestamp: 18-11-2026; 18:50 UTC

Release date: 24-03-2021